



*Injury, Violence, Physical Activity & Disability*



California Department of Public Health  
Safe and Active Communities Branch  
Naloxone Grant Program

REQUEST FOR APPLICATIONS (RFA #16-10967):  
Naloxone Distribution Projects

Informational Webinar  
April 3, 2017, 1-2 pm  
April 4, 2017, 10-11 am



Welcome

Stacy Alamo Mixson, M.P.H., Chief  
Safe and Active Communities Branch  
California Department of Public Health

Nancy Bagnato, MPH, Chief  
State and Local Injury Control Section  
Safe and Active Communities Branch

## Purpose of the Webinars

- Provide background information and an overview of the RFA
- Review key elements of the application process
- Answer questions that have been submitted



## Safe and Active Communities Branch (SACB) Efforts to Prevent Opioid Overdose

- In 2015, with funding from the Centers for Disease Control and Prevention (CDC), SACB initiated the **California Prescription Drug Overdose Prevention Initiative** to promote a multi-faceted statewide response involving many partners and a variety of strategies.
- Initiative staff also provides support to the CDPH Director's **Prescription Opioid Misuse and Overdose Prevention Workgroup** and partners with the California Healthcare Foundation to fund local opioid safety coalitions that promote safe prescribing, use of naloxone, and expansion of medically assisted treatment options.
- **Naloxone Grant Program**

# Introduction

- Senate Bill (SB) 833 (Chapter 30, Statutes of 2016) established a new Naloxone Grant Program within the California Department of Public Health (CDPH) with the goal of reducing the number of fatal overdoses in California from opioid drugs, including prescription opioids and heroin, by increasing access to the life-saving drug naloxone.
- A total of \$3 million was allocated on a one-time basis to support this program through June 30, 2019. The total available to support local implementation of the program is \$2.7 million.

## Purpose of RFA

- Through this non-competitive Request for Application (RFA) process, the CDPH Safe and Active Communities Branch (SACB) is offering grants of naloxone product (Narcan nasal spray) and funding to all 61 local health departments (LHDs) to conduct **Naloxone Distribution Projects**.
- LHDs will provide naloxone product to local programs, agencies and community-based organizations (local entities) within their jurisdictions that have naloxone distribution systems and are in the best position to save lives from opioid overdose.

## Term of Grant Award

The term of the grant award is June 1, 2017, (or upon final Grant Agreement approval by CDPH) to June 30, 2019.

## Applicant Eligibility

Governmental health departments in all 61 California local health jurisdictions are eligible and encouraged to apply to the Naloxone Grant Program.

## Product and Funding Allocation

- Funding amounts allocated for naloxone product and project administrative costs to every health jurisdiction in California based on a formula developed to maximize the potential for saving lives.
- The formula addresses the need for naloxone using data from each county to calculate an average number of opioid-involved (including heroin) overdose deaths and emergency department visits for each of the last three years.
- *A Naloxone Grant Program Local Health Department Allocations Chart*, which lists the amounts available to each LHD for the purchase of naloxone (Narcan nasal spray) and for project administration, is provided as Attachment A in the RFA.

## Purchase of Naloxone (Narcan)

- LHDs that elect to receive a grant will not purchase the naloxone product.
- In order to obtain the best purchase price, expedite the delivery of naloxone product, and avoid additional administrative burden on LHDs, CDPH/SACB will procure a bulk purchase of Narcan nasal spray from the manufacturer ADAPT Pharma.
- The manufacturer will ship the product (at no additional cost) directly to each grantee.
- Grantees can choose to have the naloxone product delivered all in one shipment or split their allocation in half and receive a second shipment in June, 2018.

## Administrative Costs

- The funding for project administration, if accepted, may be used to cover costs of: conducting outreach and assessment of local entities; receipt, storage, and distribution of naloxone product; reporting; and other activities related to project implementation.
- If accepting the allocation for administrative costs, LHDs will submit a single invoice for reimbursement of the amount to CDPH/SACB upon final CDPH approval of the Grant Agreement.
- LHDs may elect to opt out of receiving the project administration allocation and instead apply that dollar amount to the purchase of additional naloxone product.

# Grant Requirements

**1. Conduct outreach** to identify local entities within their health jurisdiction that already have a naloxone distribution system in place and have the capacity to efficiently and effectively provide naloxone and training to first responders (as described in section C, number 3 in the RFA).\*

Local entities may include harm reduction/syringe exchange programs, substance use disorder treatment providers, homeless programs, jails, emergency services providers, law enforcement, and others.

\* If a LHD identifies the need to establish a new naloxone distribution system(s) in their jurisdiction, the LHD must ensure that any new naloxone distribution system meets the definition provided.

# Definition of Naloxone Distribution Systems

- Work under a standing order from a licensed clinician/medical director;
- Have staff that are trained (or are trained to provide education to others) on:
  1. naloxone storage and administration,
  2. overdose prevention techniques,
  3. how to recognize an opioid overdose (signs and symptoms),
  4. how to respond by calling 911 and provide rescue breathing, and
  5. post-overdose care.
- Dispense naloxone products; and
- Document distribution efforts.

## Grant Requirements (cont'd)

**2. Select local entities** to receive naloxone based on the level of risk of overdose among the population(s) they serve and need for naloxone (Narcan) product.

*Priority consideration is to be given to harm reduction/syringe exchange programs, if present within the health jurisdiction. **(A list of California harm reduction/syringe exchange programs that currently have a naloxone distribution system in place is included as Attachment C of the RFA.)***

## Grant Requirements (cont'd)

**3. Submit a naloxone distribution plan** to CDPH/SACB for approval by June 16, 2017, or within 60 days of receiving CDPH final approval of the Grant Agreement.

The plan will be submitted on-line and must include the names of selected local entities, the type(s) of services they provide, a description of the target population(s) they serve, and the number of naloxone product they will receive. CDPH will provide a standardized distribution plan template.

**4. Begin distributing naloxone** product to selected local entities by July 16, 2017, or within 90 days of receiving CDPH final approval of the Grant Agreement. All naloxone must be distributed to selected local entities by September 30, 2018.

## Grant Requirements (cont'd)

**5. Document and submit a final report** to CDPH/SACB by April 1, 2019, on the distribution of naloxone for accountability and evaluation purposes.

Documentation will include:

- the local entities that received naloxone product from the grantee (e.g., organization name, type and location, date of distribution, and number of doses distributed);
- the individuals that received naloxone from the local entities; and,
- if possible, the number of overdose reversals that can be attributed to the Naloxone Grant Program.

On-line data collection forms and instructions, developed with input from grantees and other stakeholders, will be provided.

## Grant Requirements (cont'd)

### **6. Enter into a Standard Grant Agreement with CDPH.**

Attachment C of the RFA includes a Grant Agreement template, Budget Detail and Payment Provisions, Standard Grant Conditions, and Additional Provisions.

# Mandatory Letter of Interest

April 7, 2017, is the deadline for submitting the required Letter of Interest.

The letter is non-binding.

Please [complete the on-line Letter of Interest](#) which requires the following information:

- LHD County/Jurisdiction.
- Health Officer Name and contact information.
- Contact information for individual responsible for the application.
- An indication of the intent to apply (or not apply).
- An indication of the intent to receive the funding allocation dedicated for administrative needs, or a redirection of this funding toward the purchase of additional naloxone product.

## Other Available Resources

- Because this is a one-time allocation of funding, CDPH/SACB is not able to offer start-up or ongoing technical assistance or training support.
- A website for the [Naloxone Grant Program](#) has been established for grantees (and others who may be interested) that includes helpful materials and resources.
- Additional webinars may be offered that provide the opportunity to share additional information or for LHDs to share best practices and resources.



# Application Submission Instructions

- In order to initiate the development of a Grant Agreement with CDPH, applications are to be submitted [on-line](#) as soon as possible, but no later than May 1, 2017. The link is included in the RFA.
- Please submit any questions regarding the RFA or application to [ngp@cdph.ca.gov](mailto:ngp@cdph.ca.gov) by the April 17, 2017, deadline.
- All questions about this RFA opportunity and responses will be posted on the [Naloxone Grant Program](#) website by April 21, 2017.

# Grant Award Process

- On-line applications will be reviewed for completeness and the information provided will be used to develop a CDPH Grant Agreement.
- The resulting Grant Agreement will be sent to the applicant agency for signature.
- Once signed and returned to CDPH, and then signed by CDPH's Contract Management Unit, the Grant Agreement is considered fully executed.
- The purchase order for the naloxone product will be submitted upon final approval of the Grant Agreement.

## RFA Time Schedule

- RFA Release: **March 27, 2017**
- On-Line Mandatory Letter of Interest Due: **April 7, 2017**
- On-Line Applications Due to CDPH/SACB: **May 1, 2017**
- Grant Start Date: **June 1, 2017** (or upon CDPH final approval of Grant Agreement)

## Questions and Responses

- Review of questions and responses submitted prior to the webinars
- Additional questions must be submitted by April 17, 2017
- All questions and responses will be posted on the [Naloxone](#) website by April 21, 2017.

Thank you for participating in our webinar for the California  
Department of Public Health, Safe and Active Communities  
Branch,  
Naloxone Grant Program, Request For Applications (RFA  
#16-10967): Naloxone Distribution Projects

Please send any inquiries to: [ngp@cdph.ca.gov](mailto:ngp@cdph.ca.gov).  
For additional information, please go to the  
[Naloxone Grant Program](#) webpage.